Iker Núñez-Carpintero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iker Núñez-Carpintero has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Davide Cirillo
Barcelona Supercomputing Center (BSC)
9 shared publications - Alfonso Valencia
Barcelona Supercomputing Center
7 shared publications - Jon Sánchez-Valle
Barcelona Supercomputing Center
3 shared publications - Felipe Xavier Costa
Universidade Católica Portuguesa, Católica Medical School, Católica Biomedical Research Centre, 1649-023 Lisbon, Portugal
2 shared publications - Hanns Lochmüller
Faculty of Medicine, University of Ottawa, Ottawa, Canada
2 shared publications Ivailo Tournev
Department of Neurology, Expert Centre for Hereditary Neurologic and Metabolic Disorders, Alexandrovska University Hospital, Medical University-Sofia, Sofia, Bulgaria
2 shared publications
Latest Publications
- Open Access
- 30 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Sex-specific transcriptome similarity networks elucidate comorbidity relationships
Background Biological differences between women and men lead to variations in the prevalence and progression of many diseases, influencing diagnosis, management, and treatment outcomes. However, the biological mechanisms that contribute to sex differences in disease co-occurrence remain largely unexplored. This study aims to uncover the molecular processes underlying sex-specific patterns of comorbidity. Methods We analyze gene expression data from over 100 diseases, considering the biological sex of each sample (8906 samples, 43.06% women). For each sex, we construct disease similarity networks based on differential gene expression profiles and identify enriched biological processes. We then compare these networks with epidemiological data from population-level comorbidity studies to assess their concordance. Finally, we investigate drugs associated with sex-specific comorbidities to identify potential differences in therapeutic response. Results We show that 13–16% of transcriptomically similar disease pairs are sex-specific. These similarities recover 53–60% of known comorbidities that differ between women and men. Diseases can co-occur through the differential alteration of biological processes, with immune and metabolic pathways playing a greater role in women, and extracellular matrix organization and signal transduction pathways in men. We also identify drugs differentially linked to comorbid diseases depending on sex, suggesting possible sex-dependent effects on disease co-occurrence. Conclusions Our findings demonstrate that transcriptomic data can reveal sex-specific molecular links between diseases and suggest that biological sex should be considered in the design of therapeutic strategies and drug administration.
- 30 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessSex-specific transcriptome similarity networks elucidate comorbidity relationships
Background Biological differences between women and men lead to variations in the prevalence and progression of many diseases, influencing diagnosis, management, and treatment outcomes. However, the biological mechanisms that contribute to sex differences in disease co-occurrence remain largely unexplored. This study aims to uncover the molecular processes underlying sex-specific patterns of comorbidity. Methods We analyze gene expression data from over 100 diseases, considering the biological sex of each sample (8906 samples, 43.06% women). For each sex, we construct disease similarity networks based on differential gene expression profiles and identify enriched biological processes. We then compare these networks with epidemiological data from population-level comorbidity studies to assess their concordance. Finally, we investigate drugs associated with sex-specific comorbidities to identify potential differences in therapeutic response. Results We show that 13–16% of transcriptomically similar disease pairs are sex-specific. These similarities recover 53–60% of known comorbidities that differ between women and men. Diseases can co-occur through the differential alteration of biological processes, with immune and metabolic pathways playing a greater role in women, and extracellular matrix organization and signal transduction pathways in men. We also identify drugs differentially linked to comorbid diseases depending on sex, suggesting possible sex-dependent effects on disease co-occurrence. Conclusions Our findings demonstrate that transcriptomic data can reveal sex-specific molecular links between diseases and suggest that biological sex should be considered in the design of therapeutic strategies and drug administration.
- Open Access
A conserved transcriptional backbone and rewiring of gene-regulatory networks in activated human CD4⁺ T cells
CD4+ T cells are components of the adaptive immune system with a plethora of subtype-specific functions. In order to further dissect the activation and differentiation regulatory program(s) of individual CD4+ T cell subsets, we performed an in vitro activation and differentiation of human primary naive CD4+ T cells towards Th1, Th2, Th17 and Treg subtypes followed by the single-cell RNA-seq and ATAC-seq (multiome) analysis. Resulting multiome data were used for constructing the subtype-specific gene regulatory networks, which were next assessed for their differences/similarities among the subtypes. Surprisingly, a conserved set of 8 "backbone" transcription factors (TFs) was identified as highly central in all subtypes, however, with unique differentiation-driven rewiring tendency. Subtype-specific "driver" TFs were identified in the case of Th1-Th1_17-Th17 lineage (EOMES, HLF), naive Tregs (ESR1, DACH1), and memory Tregs (SOX13). Finally, we applied community detection algorithms to identify potential non-obvious groups of genes that regulate diverse molecular functions within the differentiated subtypes, linked to the backbone TFs. Our atlas aims at providing a high resolution understanding of the gene regulatory networks and their rewiring in human primary CD4+ T cells, upon activation and differentiation.
Open AccessA conserved transcriptional backbone and rewiring of gene-regulatory networks in activated human CD4⁺ T cells
CD4+ T cells are components of the adaptive immune system with a plethora of subtype-specific functions. In order to further dissect the activation and differentiation regulatory program(s) of individual CD4+ T cell subsets, we performed an in vitro activation and differentiation of human primary naive CD4+ T cells towards Th1, Th2, Th17 and Treg subtypes followed by the single-cell RNA-seq and ATAC-seq (multiome) analysis. Resulting multiome data were used for constructing the subtype-specific gene regulatory networks, which were next assessed for their differences/similarities among the subtypes. Surprisingly, a conserved set of 8 "backbone" transcription factors (TFs) was identified as highly central in all subtypes, however, with unique differentiation-driven rewiring tendency. Subtype-specific "driver" TFs were identified in the case of Th1-Th1_17-Th17 lineage (EOMES, HLF), naive Tregs (ESR1, DACH1), and memory Tregs (SOX13). Finally, we applied community detection algorithms to identify potential non-obvious groups of genes that regulate diverse molecular functions within the differentiated subtypes, linked to the backbone TFs. Our atlas aims at providing a high resolution understanding of the gene regulatory networks and their rewiring in human primary CD4+ T cells, upon activation and differentiation.
- Open Access
Sex-specific transcriptome similarity networks elucidate comorbidity relationships
Humans present sex-driven biological differences. Consequently, the prevalence of analyzing specific diseases and comorbidities differs between the sexes, directly impacting patients’ management and treatment. Despite its relevance and the growing evidence of said differences across numerous diseases (with 4,370 PubMed results published within the past year), knowledge at the comorbidity level remains limited. In fact, to date, no study has attempted to identify the biological processes altered differently in women and men, promoting differences in comorbidities. To shed light on this problem, we analyze expression data for more than 100 diseases from public repositories, analyzing each sex independently. We calculate similarities between differential expression profiles by disease pairs and find that 13-16% of transcriptomically similar disease pairs are sex-specific. By comparing these results with epidemiological evidence, we recapitulate 53-60% of known comorbidities distinctly described for men and women, finding sex-specific transcriptomic similarities between sex-specific comorbid diseases. The analysis of shared underlying pathways shows that diseases can co-occur in men and women by altering alternative biological processes. Finally, we identify different drugs differentially associated with comorbid diseases depending on patients’ sex, highlighting the need to consider this relevant variable in the administration of drugs due to their possible influence on comorbidities.
Open AccessSex-specific transcriptome similarity networks elucidate comorbidity relationships
Humans present sex-driven biological differences. Consequently, the prevalence of analyzing specific diseases and comorbidities differs between the sexes, directly impacting patients’ management and treatment. Despite its relevance and the growing evidence of said differences across numerous diseases (with 4,370 PubMed results published within the past year), knowledge at the comorbidity level remains limited. In fact, to date, no study has attempted to identify the biological processes altered differently in women and men, promoting differences in comorbidities. To shed light on this problem, we analyze expression data for more than 100 diseases from public repositories, analyzing each sex independently. We calculate similarities between differential expression profiles by disease pairs and find that 13-16% of transcriptomically similar disease pairs are sex-specific. By comparing these results with epidemiological evidence, we recapitulate 53-60% of known comorbidities distinctly described for men and women, finding sex-specific transcriptomic similarities between sex-specific comorbid diseases. The analysis of shared underlying pathways shows that diseases can co-occur in men and women by altering alternative biological processes. Finally, we identify different drugs differentially associated with comorbid diseases depending on patients’ sex, highlighting the need to consider this relevant variable in the administration of drugs due to their possible influence on comorbidities.
- Open Access
Exploring the Boundaries of Medulloblastoma Subgroups with Synthetic Data Generation
Medulloblastoma is a childhood brain tumor traditionally classified into four molecular subgroups. Recent evidence suggests that Groups 3 and 4 represent a biological continuum rather than distinct entities, a paradigm shift with significant implications for understanding disease biology and treatment strategies. Nevertheless, assessing this hypothesis is challenging mainly due to data scarcity. In this study, we utilize transcriptomics data to provide evidence supporting the existence of an intermediate subgroup between Groups 3 and 4 with distinct molecular features. Leveraging synthetic data generation with a Variational Autoencoder, we address data scarcity limitations effectively. Our findings are corroborated by prior studies employing different methodologies and datasets, further reinforcing the robustness of our results. Additionally, we apply explainability techniques to the VAE, uncovering key relationships between gene expression and disease subgroups. This study demonstrates the potential of synthetic data generation to refine rare disease subtyping and advance our understanding of the underlying biological mechanisms.
Open AccessExploring the Boundaries of Medulloblastoma Subgroups with Synthetic Data Generation
Medulloblastoma is a childhood brain tumor traditionally classified into four molecular subgroups. Recent evidence suggests that Groups 3 and 4 represent a biological continuum rather than distinct entities, a paradigm shift with significant implications for understanding disease biology and treatment strategies. Nevertheless, assessing this hypothesis is challenging mainly due to data scarcity. In this study, we utilize transcriptomics data to provide evidence supporting the existence of an intermediate subgroup between Groups 3 and 4 with distinct molecular features. Leveraging synthetic data generation with a Variational Autoencoder, we address data scarcity limitations effectively. Our findings are corroborated by prior studies employing different methodologies and datasets, further reinforcing the robustness of our results. Additionally, we apply explainability techniques to the VAE, uncovering key relationships between gene expression and disease subgroups. This study demonstrates the potential of synthetic data generation to refine rare disease subtyping and advance our understanding of the underlying biological mechanisms.
- Open Access
- 28 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes
Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network community detection analysis of complementary biomedical information provided by relevant data sources, namely protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases.
- 28 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessRare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes
Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network community detection analysis of complementary biomedical information provided by relevant data sources, namely protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases.
- Open Access
- 6 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer
We introduce Promoter-Enhancer-Guided Interaction Networks (PENGUIN), a method for studying protein-protein interaction (PPI) networks within enhancer-promoter interactions. PENGUIN integrates H3K27ac-HiChIP data with tissue-specific PPIs to define enhancer-promoter PPI networks (EPINs). We validated PENGUIN using cancer (LNCaP) and benign (LHSAR) prostate cell lines. Our analysis detected EPIN clusters enriched with the architectural protein CTCF, a regulator of enhancer-promoter interactions. CTCF presence was coupled with the prevalence of prostate cancer (PrCa) single nucleotide polymorphisms (SNPs) within the same EPIN clusters, suggesting functional implications in PrCa. Within the EPINs displaying enrichments in both CTCF and PrCa SNPs, we also show enrichment in oncogenes. We substantiated our identified SNPs through CRISPR/Cas9 knockout and RNAi screens experiments. Here we show that PENGUIN provides insights into the intricate interplay between enhancer-promoter interactions and PPI networks, which are crucial for identifying key genes and potential intervention targets. A dedicated server is available at https://penguin.life.bsc.es/.
- 6 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessThe PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer
We introduce Promoter-Enhancer-Guided Interaction Networks (PENGUIN), a method for studying protein-protein interaction (PPI) networks within enhancer-promoter interactions. PENGUIN integrates H3K27ac-HiChIP data with tissue-specific PPIs to define enhancer-promoter PPI networks (EPINs). We validated PENGUIN using cancer (LNCaP) and benign (LHSAR) prostate cell lines. Our analysis detected EPIN clusters enriched with the architectural protein CTCF, a regulator of enhancer-promoter interactions. CTCF presence was coupled with the prevalence of prostate cancer (PrCa) single nucleotide polymorphisms (SNPs) within the same EPIN clusters, suggesting functional implications in PrCa. Within the EPINs displaying enrichments in both CTCF and PrCa SNPs, we also show enrichment in oncogenes. We substantiated our identified SNPs through CRISPR/Cas9 knockout and RNAi screens experiments. Here we show that PENGUIN provides insights into the intricate interplay between enhancer-promoter interactions and PPI networks, which are crucial for identifying key genes and potential intervention targets. A dedicated server is available at https://penguin.life.bsc.es/.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4399
Molecular COPD Heterogeneity Uncovered by Multi-layer Network Analysis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4399
Molecular COPD Heterogeneity Uncovered by Multi-layer Network Analysis
- Open Access
Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes
Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network analysis of protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. We explore this in more detail for one of the proteins not previously associated with the NMJ, USH2A. Loss of the zebrafish USH2A ortholog revealed some effects on early movement and gross NMJ morphology. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases.
Open AccessRare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes
Exploring the molecular basis of disease severity in rare disease scenarios is a challenging task provided the limitations on data availability. Causative genes have been described for Congenital Myasthenic Syndromes (CMS), a group of diverse minority neuromuscular junction (NMJ) disorders; yet a molecular explanation for the phenotypic severity differences remains unclear. Here, we present a workflow to explore the functional relationships between CMS causal genes and altered genes from each patient, based on multilayer network analysis of protein-protein interactions, pathways and metabolomics. Our results show that CMS severity can be ascribed to the personalized impairment of extracellular matrix components and postsynaptic modulators of acetylcholine receptor (AChR) clustering. We explore this in more detail for one of the proteins not previously associated with the NMJ, USH2A. Loss of the zebrafish USH2A ortholog revealed some effects on early movement and gross NMJ morphology. This work showcases how coupling multilayer network analysis with personalized -omics information provides molecular explanations to the varying severity of rare diseases; paving the way for sorting out similar cases in other rare diseases.